SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Keyword(s):
Keyword(s):
2019 ◽
Keyword(s):
2005 ◽
Vol 23
(16_suppl)
◽
pp. 4045-4045
◽
Keyword(s):
2019 ◽
2008 ◽
Vol 26
(15_suppl)
◽
pp. 4512-4512
◽
Keyword(s):
Keyword(s):